logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
T

Taishi Harada

fukuchiyama city hospital
H指数:32
被引数:3,854

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC

TTF-1表达对PD-L1阴性NSCLC患者接受双重ICI与化疗联合免疫疗法预后分层的预测价值

International Journal of Clinical Oncology
IF2.8
2026-08-040
PRE
Naoya Nishioka; Daiki Murata; Koichi Azuma; Kazuhiro Ito; Takashi Nomizo; Kazuhiko Yamada; Tatsuya Imabayashi; Kentaro Iwanaga; Kenji Chibana; Takayo Ota; Yuuya Nishii; Akira Nakao; Asuka Okada; Kosuke Hamai; Takenori Sakai; Taishi Harada; Keiko Tanimura; Kohei Yoshimine; Yosuke Tamura; Ryuichiro Takaki; Yasuhiro Goto; Makoto Hibino; Tomohiro Oba; Toshiyuki Sumi; Hiroyasu Kaneda; Tadaaki Yamada; Koichi Takayama
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria

识别PD-L1高表达非小细胞肺癌中隐藏恶病质亚组：AWGC与Fearon标准的比较分析

journal of cachexia, sarcopenia and muscle
IF0
2026-04-120
OAAI
Naoya Nishioka; Hayato Kawachi; Tadaaki Yamada; Motohiro Tamiya; Yoshiki Negi; Yasuhiro Goto; Akira Nakao; Shinsuke Shiotsu; Keiko Tanimura; Takayuki Takeda; Asuka Okada; Taishi Harada; Koji Date; Yusuke Chihara; Isao Hasegawa; Nobuyo Tamiya; Takeo Ogawa; Masahiro Iwasaku; Shinsaku Tokuda; Takashi Kijima; Koichi Takayama
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy

基于炎症选择最优免疫疗法：用于PD-L1 ≥50%基因突变阴性IV期非小细胞肺癌：帕博利珠单抗单药治疗与联合化疗免疫疗法

TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2025-11-300
PRE
Kunimatsu, Yusuke; Nishioka, Naoya; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Ishida, Masaki; Kijima, Takashi; Takayama, Koichi
IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non–small cell lung cancer

IFITM3-MET相互作用通过AKT通路激活驱动EGFR突变非小细胞肺癌的奥希替尼耐药性

Molecular Cancer
IF33.9
2025-10-290
OAAI
Ritsu Ibusuki; Eiji Iwama; Atsushi Shimauchi; Hiromu Kawano; Shun Mizusaki; Satoshi Nakamura; Yui Miyazaki; Yu Inutsuka; Mikiko Hashisako; Taishi Harada; Yuko Tsuchiya-Kawano; Hirono Tsutsumi; Takayuki Nakanishi; Noriaki Nakagaki; Yuichiro Koga; Shinichi Kimura; Shun Mashimoto; Daisuke Shibahara; Kohei Otsubo; Yasuto Yoneshima; Kentaro Tanaka; Yoshinao Oda; Isamu Okamoto
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations

EGFR激活突变阳性的非小细胞肺癌患者在接受EGFR酪氨酸激酶抑制剂治疗期间化疗的生物学影响

Lung Cancer
IF4.4
2025-09-160
OAAI
Eiji Iwama; Kazuko Sakai; Taishi Harada; Shintaro Kanda; Shunichi Sugawara; Toshihide Yokoyama; Hirokazu Taniguchi; Kaoru Tanaka; Ryo Toyozawa; Kenichi Koyama; Yoshitaka Zenke; Gen Kida; Yasuhiko Nishioka; Hiroshi Yokouchi; Masayuki Hirose; Kazuto Nishio; Nobuyuki Yamamoto; Yuichiro Ohe; Isamu Okamoto
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102)

阿特珠单抗联合卡铂和nab-紫杉醇组合疗法治疗TTF-1阴性晚期非鳞状非小细胞肺癌：一项多中心、单臂II期试验（F1NE TUNE，LOGiK 2102）

European Journal of Cancer
IF7.1
2025-09-120
PREAI
Yoshimasa Shiraishi; Takayuki Shimose; Motoko Tachihara; Yuko Tsuchiya-Kawano; Ryotaro Morinaga; Hiroyuki Inoue; Yukihiro Toi; Tadaaki Yamada; Masafumi Yamaguchi; Kosuke Kashiwabara; Kazunori Tobino; Hidenobu Ishii; Yoshihiko Sakata; Megumi Inaba; Kazuhisa Nakashima; Kenji Chibana; Tomoya Fukui; Miiru Izumi; Ryota Saito; Hiroshi Ishii; Shota Omori; Shinsuke Ogusu; Kazuto Furuyama; Satoru Miura; Taishi Harada; Isamu Okamoto
Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab

培美曲塞联合铂类药物作为接受纳武利尤单抗联合伊匹木单抗治疗的患者中，恶性胸膜间皮瘤的二线治疗方案。

Lung Cancer
IF4.4
2025-08-120
PRE
Sawana Ono; Hirokazu Taniguchi; Koji Kuroda; Teppei Hashimoto; Asuka Okada; Yasuhiro Goto; Hidenori Kitai; Yoichi Nakamura; Shinsuke Ogusu; Tetsunari Hase; Takayo Ota; Noriyuki Ebi; Makoto Furugen; Taishi Harada; Yoshiaki Kinoshita; Takaki Mizoguchi; Katsumi Nakatomi; Yoshifumi Soejima; Takahiro Yamada; Shinnosuke Takemoto; Hiroshi Mukae
Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

携带EGFR突变的患者在EGFR-TKI失败后接受铂类为基础的系统治疗中不良预后因素及治疗策略的分析

Clinical Lung Cancer
IF3.3
2025-07-220
PRE
Tae Hata; Tadaaki Yamada; Naoki Furuya; Hisashi Tanaka; Akihiro Yoshimura; Tomohiro Oba; Makoto Hibino; Takahito Fukuda; Yasuhiro Goto; Akira Nakao; Shinsuke Ogusu; Yuta Okazaki; Taishi Harada; Takayo Ota; Ken Masubuchi; Koji Mikami; Shoki Matsumoto; Ryoichi Honda; Koji Date; Yusuke Chihara
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study

EGFR突变非小细胞肺癌在EGFR-TKI治疗失败后，化疗免疫疗法批准前后真实世界治疗结局：一项日本队列研究

international journal of oncology
IF2.8
2025-07-220
PRE
Kenji Morimoto; Tadaaki Yamada; Naoki Furuya; Hisashi Tanaka; Akihiro Yoshimura; Tomohiro Oba; Makoto Hibino; Takahito Fukuda; Yasuhiro Goto; Akira Nakao; Shinsuke Ogusu; Yuta Okazaki; Taishi Harada; Takayo Ota; Ken Masubuchi; Koji Mikami; Tae Hata; Shoki Matsumoto; Ryoichi Honda; Koji Date; Yusuke Chihara; Koichi Takayama
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy
ONCOIMMUNOLOGY
IF6.3
2024-12-160
OAAI
Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Kijima, Takashi; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Shimose, Takayuki; Takayama, Koichi
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
INVESTIGATIONAL NEW DRUGS
IF2.7
2024-08-210
PRE
Tachibana, Yusuke; Morimoto, Kenji; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study
TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2024-08-010
OAAI
Kataoka, Nobutaka; Katayama, Yuki; Yamada, Tadaaki; Morimoto, Kenji; Takeda, Takayuki; Okada, Asuka; Shiotsu, Shinsuke; Chihara, Yusuke; Yamada, Takahiro; Hiranuma, Osamu; Ota, Takahiro; Harada, Taishi; Hasegawa, Isao; Nishioka, Naoya; Iwasaku, Masahiro; Tokuda, Shinsaku; Takayama, Koichi
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study
FRONTIERS IN IMMUNOLOGY
IF5.9
2024-07-150
OAAI
Nishioka, Naoya; Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Masui, Taiki; Sai, Natsuki; Ishida, Masaki; Katayama, Yuki; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi
Association between clinical characteristics and treatment outcome of immune checkpoint inhibitor with or without chemotherapy in elderly non-small cell lung cancer patients with high PD-L1 expression
CANCER RESEARCH
IF16.6
2024-03-220
PRE
Kawachi, Hayato; Takei, Shota; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Kijima, Takashi; Takayama, Koichi
Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study
JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2024-03-010
OA
Katayama, Yuki; Yamada, Tadaaki; Morimoto, Kenji; Fujii, Hiroyuki; Morita, Satomi; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Shiotsu, Shinsuke; Chihara, Yusuke; Hiranuma, Osamu; Yamada, Takahiro; Ota, Takahiro; Harada, Taishi; Hasegawa, Isao; Iwasaku, Masahiro; Tokuda, Shinsaku; Tanaka, Noriyuki; Miyagawa-Hayashino, Aya; Takayama, Koichi
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%

免疫检查点抑制剂联合化疗对TPS ≥ 50% 的老年非小细胞肺癌PD-L1预后的影响

FRONTIERS IN IMMUNOLOGY
IF5.9
2024-02-232
OAAI
Takei, Shota; Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi
A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
JTO CLINICAL AND RESEARCH REPORTS
IF3.5
2023-12-011
OA
Wakuda, Kazushige; Yamaguchi, Hiroyuki; Kenmotsu, Hirotsugu; Fukuda, Minoru; Ito, Kentaro; Tsuchiya-Kawano, Yuko; Tanaka, Kentaro; Harada, Taishi; Nakatani, Yuki; Miura, Satoru; Yokoyama, Toshihide; Nakamura, Tomomi; Izumi, Miiru; Nakamura, Atsushi; Ikeda, Satoshi; Takayama, Koichi; Yoshimura, Kenichi; Nakagawa, Kazuhiko; Yamamoto, Nobuyuki; Sugio, Kenji
Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry
BMJ OPEN RESPIRATORY RESEARCH
IF3.4
2023-11-1410
OAAI
Tsubouchi, Kazuya; Hamada, Naoki; Tokunaga, Shoji; Ichiki, Katsuyuki; Takata, Shohei; Ishii, Hiroshi; Kitasato, Yasuhiko; Okamoto, Masaki; Kawakami, Satoru; Yatera, Kazuhiro; Kawasaki, Masayuki; Fujita, Masaki; Yoshida, Makoto; Maeyama, Takashige; Harada, Taishi; Wataya, Hiroshi; Torii, Ryo; Komori, Masashi; Mizuta, Yuichi; Tobino, Kazunori; Harada, Eiji; Yabuuchi, Hidetake; Nakanishi, Yoichi; Okamoto, Isamu

研究方向

暂未获取到该数据
K
Koichi Takayama
H 指数:75论文数:954被引数:1.9万
T
Tadaaki Yamada
H 指数:41论文数:563被引数:6,290
Y
Yusuke Chihara
H 指数:23论文数:157被引数:3,149
S
Shinsuke Shiotsu
H 指数:17论文数:121被引数:1,391
T
Takayuki Takeda
H 指数:22论文数:196被引数:2,735
Y
Yasuhiro Gotô
H 指数:31论文数:334被引数:3,794
M
Masahiro Iwasaku
H 指数:24论文数:135被引数:1,895
K
Koji Date
H 指数:8论文数:45被引数:168
A
Asuka Okada
H 指数:11论文数:105被引数:402
I
Isao Hasegawa
H 指数:33论文数:311被引数:4,770